VP2-2024: Fuzuloparib with or without apatinib in HER2- metastatic breast cancer (mBC) patients (pts) with germline BRCA1/2 mutations (gBRCA1/2m): A randomized phase III trial

Fuzuloparib is an oral poly (ADP–ribose) polymerase inhibitor (PARPi) that has promising antitumor activity in pts with BRCAm. The combination of an anti-angiogenic agent with a PARPi improved clinical outcomes in gynecological cancers. Here we assessed fuzuloparib with or without apatinib, a VEGFR2 inhibitor, for treating HER2- mBC pts with gBRCA1/2m.